Eisai (ESALY) News Today → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free ESALY Stock Alerts $61.51 -1.33 (-2.11%) (As of 01/30/2023) Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative March 29, 2024 | wsj.comEisai Co. Ltd. ADRMarch 23, 2024 | reuters.comEisai Co LtdMarch 20, 2024 | morningstar.comEisai Co Ltd 4523February 15, 2024 | finance.yahoo.comBIIB Mar 2024 210.000 callFebruary 15, 2024 | finance.yahoo.comBIIB Feb 2024 227.500 callFebruary 15, 2024 | finance.yahoo.comBIIB Mar 2024 235.000 callFebruary 14, 2024 | finance.yahoo.comBIIB Mar 2024 205.000 putJanuary 12, 2024 | seekingalpha.comESALF Eisai Co., Ltd.December 8, 2023 | markets.businessinsider.comMerck Says Phase 3 LEAP-001 Trial Evaluating KEYTRUDA Plus LENVIMA Did Not Meet EndpointsSeptember 25, 2023 | msn.comJapan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment LeqembiSeptember 22, 2023 | msn.comMerck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung CancerJuly 10, 2023 | marketbeat.comBiogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi (ESALY)Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout.July 6, 2023 | markets.businessinsider.comFDA Grants Traditional Approval To Eisai's Leqembi To Treat Adult Patients With Alzheimer's DiseaseJune 13, 2023 | benzinga.comAlzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare ResourcesJune 11, 2023 | markets.businessinsider.comFDA Panel Recommends Full Approval For Biogen And Eisai's Alzheimer's Drug LeqembiJune 8, 2023 | msn.comBernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'January 9, 2023 | finance.yahoo.comUTHR or ESALY: Which Is the Better Value Stock Right Now?January 6, 2023 | finance.yahoo.comFDA approves treatment for people with mild forms of Alzheimer’sNovember 30, 2022 | finance.yahoo.comDespite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's CandidateNovember 30, 2022 | seekingalpha.comBiogen rallies Alzheimer’s drug developers after full data for lecanemabNovember 30, 2022 | finance.yahoo.comOpen Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer'sNovember 30, 2022 | seekingalpha.comBiogen's lecanemab shows less cognitive decline with Alzheimer's, but more brain swellingNovember 30, 2022 | barrons.comBiogen and Eisai’s Alzheimer’s Data Confirm Benefit. Questions Still Loom.November 28, 2022 | seekingalpha.comBiogen drops after report on second death linked to Alzheimer’s candidateNovember 28, 2022 | finance.yahoo.comUTHR vs. ESALY: Which Stock Is the Better Value Option?November 17, 2022 | msn.comAfter Rallying 50% in the Last 2 Months, Is Biogen Stock Still a Buy?November 15, 2022 | finance.yahoo.comRoche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate LingersNovember 2, 2022 | marketbeat.comFY2024 Earnings Estimate for Eisai Co., Ltd. (OTCMKTS:ESALY) Issued By Jefferies Financial GroupEisai Co., Ltd. (OTCMKTS:ESALY - Get Rating) - Equities research analysts at Jefferies Financial Group dropped their FY2024 earnings estimates for Eisai in a research report issued on Sunday, October 30th. Jefferies Financial Group analyst S. Barker now forecasts that the company will post earninOctober 29, 2022 | msn.comPatient Death in Alzheimer's Study May Limit Drug's ReachOctober 18, 2022 | seekingalpha.comBiogen Alzheimer’s data de-risked beta amyloid hypothesis - Roche executiveOctober 18, 2022 | finance.yahoo.comDespite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say ResearchersSeptember 29, 2022 | investing.comBiogen shares soar on landmark Alzheimer's data, lift rivalsSeptember 28, 2022 | seekingalpha.comMany Alzheimer's drug developers close significantly higher thanks to Biogen, Eisai dataSeptember 28, 2022 | finance.yahoo.comThis Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS ApprovalSeptember 28, 2022 | markets.businessinsider.com2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug DataSeptember 28, 2022 | investing.comAnalysis-Alzheimer's drug breakthrough big boost for Roche, Eli LillySeptember 28, 2022 | seekingalpha.comBiogen, Eisai drive rally in Alzheimer’s stocks as lecanemab succeeds in late-stage trialSeptember 28, 2022 | realmoney.thestreet.comBiogen and Lilly: How I'm Playing the Alzheimer's Drug Stocks GameSeptember 28, 2022 | msn.comIs This the First Alzheimer's Drug to Actually Work?September 28, 2022 | investing.comEisai says Alzheimer's drug succeeds in slowing cognitive declineSeptember 28, 2022 | seekingalpha.comBiogen, Eisai Alzheimer's candidate lecanemab meets primary endpoint in late-stage trialSeptember 27, 2022 | barrons.comPharmaceutical Makers Eisai and Biogen Claim Success in Latest Alzheimer’s Drug TrialSeptember 24, 2022 | fool.comEisai Co., Ltd (ADR) (OTC: ESALY)September 23, 2022 | barrons.comCan We Beat Alzheimer’s? Biogen and Eisai’s Latest Drug Trial Will Offer Clues.September 18, 2022 | seekingalpha.comESALY Eisai Co., Ltd.September 12, 2022 | finance.yahoo.comMerck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver CancerAugust 16, 2022 | investing.comEisai Co., Ltd. (4523)August 6, 2022 | seekingalpha.comEisai Co., Ltd. (ESALY) Management on Q1 2023 Results - Earnings Call TranscriptAugust 6, 2022 | markets.businessinsider.comEisai is about to announce its earnings — here's what to expectJuly 29, 2022 | markets.businessinsider.comEisai Announces Key Executive Appointment for Alzheimer's Disease Leadership Get Eisai News Delivered to You Automatically Sign up to receive the latest news and ratings for ESALY and its competitors with MarketBeat's FREE daily newsletter. Email Address Why Is Gold On a MASSIVE rally? (Ad)Gold has been on a tear this year. The yellow metal has hit an all-time high of $2,4231.29 recently and the rally could be far from over. From central banks to even Costco customers, it seems everyone is buying gold these days. With Wall Street watching the gold space carefully, now is a perfect time to pay attention to this stock. This Little known Company is a uniquely structured for profit ESALY Media Mentions By Week ESALY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESALY News Sentiment▼0.000.54▲Average Medical News Sentiment ESALY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESALY Articles This Week▼00▲ESALY Articles Average Week Get Eisai News Delivered to You Automatically Sign up to receive the latest news and ratings for ESALY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SDZNY News Today SGIOY News Today ERFSF News Today SSMXY News Today RCDTF News Today SKHHY News Today AMFPF News Today ACBFF News Today SBMFF News Today APNHY News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ESALY) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressThe Next Industry Being Reshaped By AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetryMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eisai Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
